Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The results showed that calcimimetics users showed favorable survival compared to PTX and significantly better outcomes than UC; vitamin D and its analog users had worse outcomes compared to PTX but remained better than UC; phosphate binder users showed no significant difference from PTX and were better than UC (Supplementary Fig. 3).

Source: Cox proportional hazards regression. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This multicenter retrospective cohort study included CKD stages 4 to 5 patients with PTH < 150 pg/mL from the China Renal Data System, categorized into parathyroidectomy (PTX), Drug, and Unknown Causes (UC) groups based on low PTH etiology.

Source: Abstract.

Participants were categorized according to their medication prescriptions and surgical history.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Prognosis comparison in chronic kidney disease stages 4 to 5 patients with low parathyroid hormone level due to different causes

Cohort study · BMC Nephrology · 2026

Original publication title

Prognosis comparison in chronic kidney disease stages 4 to 5 patients with low parathyroid hormone level due to different causes

Xiao Zhang; Junzhe Chen; Yi Lu; Sha Fu; Chun Ye; Hai Huang; Qiang Liu; Sheng Nie; Ying Tang

© The Author(s) 2026

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Pharmacological therapy and PTX were associated with more favorable survival profiles than low PTH of unknown causes in patients with advanced CKD, though residual confounding due to baseline differences between groups cannot be fully excluded.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Existing studies have focused on secondary hyperparathyroidism with elevated PTH in CKD, but survival outcomes of CKD patients with low PTH remain underexplored. This study examines prognostic implications of PTH reduction from different etiologies.

Source: Background

Abstract: What methods does the paper describe?

This multicenter retrospective cohort study included CKD stages 4 to 5 patients with PTH < 150 pg/mL from the China Renal Data System, categorized into parathyroidectomy (PTX), Drug, and Unknown Causes (UC) groups based on low PTH etiology. Mortality was analyzed using Kaplan-Meier curves and Cox regression. Covariates were selected by univariate or LASSO regression. Inverse probability weighting was applied in sensitivity analyses to reduce confounding.

Source: Methods

Abstract: Results

A total of 17 175 patients were included: 423 in the PTX group, 10 519 in the Drug group, and 6 233 in the UC group. PTX group had the highest survival rate (79.44%) and lowest cardiovascular mortality (1.61%), followed by Drug group (69.21% and 4.60%) and UC group (50.76% and 9.83%) (all P < 0.01). Both Drug group and UC group were consistently associated with significantly higher mortality risk compared with the PTX group (both P < 0.05). After applying IPW to balance key covariates, PTX group remained associated with the lowest mortality risk (both P < 0.05).

However, in some sensitivity analyses, no significant difference was observed between PTX group and Drug group.

Source: Results

Abstract: Conclusions

Pharmacological therapy and PTX were associated with more favorable survival profiles than low PTH of unknown causes in patients with advanced CKD, though residual confounding due to baseline differences between groups cannot be fully excluded.

Source: Conclusions
Authors’ abstract

Background

Existing studies have focused on secondary hyperparathyroidism with elevated PTH in CKD, but survival outcomes of CKD patients with low PTH remain underexplored. This study examines prognostic implications of PTH reduction from different etiologies.

Methods

This multicenter retrospective cohort study included CKD stages 4 to 5 patients with PTH < 150 pg/mL from the China Renal Data System, categorized into parathyroidectomy (PTX), Drug, and Unknown Causes (UC) groups based on low PTH etiology. Mortality was analyzed using Kaplan-Meier curves and Cox regression. Covariates were selected by univariate or LASSO regression. Inverse probability weighting was applied in sensitivity analyses to reduce confounding.

Results

A total of 17 175 patients were included: 423 in the PTX group, 10 519 in the Drug group, and 6 233 in the UC group. PTX group had the highest survival rate (79.44%) and lowest cardiovascular mortality (1.61%), followed by Drug group (69.21% and 4.60%) and UC group (50.76% and 9.83%) (all P < 0.01). Both Drug group and UC group were consistently associated with significantly higher mortality risk compared with the PTX group (both P < 0.05). After applying IPW to balance key covariates, PTX group remained associated with the lowest mortality risk (both P < 0.05).

However, in some sensitivity analyses, no significant difference was observed between PTX group and Drug group.

Conclusions

Pharmacological therapy and PTX were associated with more favorable survival profiles than low PTH of unknown causes in patients with advanced CKD, though residual confounding due to baseline differences between groups cannot be fully excluded.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12882-026-05202-7.

Publication and source details

Original title: Prognosis comparison in chronic kidney disease stages 4 to 5 patients with low parathyroid hormone level due to different causes

Xiao Zhang; Junzhe Chen; Yi Lu; Sha Fu; Chun Ye; Hai Huang; Qiang Liu; Sheng Nie; Ying Tang

BMC Nephrology · 2026

© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Guangzhou Science and Technology Projects2024A04J4722Zhang Xiao https://doi.org/10.13039/501100003453Natural Science Foundation of Guangdong Province2023A1515010149Fu Sha

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:06:57.459542+00:00

DOI: 10.1186/s12882-026-05202-7 · PMC13660033